Pelthos Therapeutics Acquires Xeglyze® (abametapir), an FDA‑Approved Topical Head Lice Treatment

Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company focused on commercializing innovative therapies, announced it has acquired Xeglyze® (abametapir), a topical prescription treatment for head lice infestation, from Australian biotech Hatchtech Pty Ltd. for $1.8 million. Xeglyze is FDA‑approved for patients aged 6 months and older and is distinguished by its single, 10‑minute application that eliminates the need for nit combing, potentially offering superior ovicidal and lousicidal activity compared with existing products. Under the deal, Pelthos gains worldwide commercialization rights with no future milestone, royalty, or extra payments owed to Hatchtech. Pelthos plans to relaunch Xeglyze in the first half of 2027 and integrate it into its growing portfolio alongside other innovative treatments. According to Pelthos CEO Scott Plesha, the acquisition adds a highly differentiated, FDA‑approved product that aligns with the company’s strategy to address unmet patient needs and deliver long‑term shareholder value. Head lice infestations are common among preschool and elementary‑age children in the U.S., with an estimated 6 to 12 million cases annually. Pediatrician Stephen W. Stripling noted that most existing lice treatments require multiple applications and have limited ovicidal activity, while Xeglyze’s profile may offer a more effective approach. #PelthosTherapeutics #Xeglyze #HeadLiceTreatment #BiotechNews #SlimScan #GrowthStocks #CANSLIM